Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
FEBS Lett ; 583(16): 2691-9, 2009 Aug 20.
Artículo en Inglés | MEDLINE | ID: mdl-19527723

RESUMEN

Misfolding is an inherent and potentially problematic propensity of proteins. Misfolded proteins tend to aggregate and the deposition of aggregated proteins is associated with a variety of highly debilitating diseases known as amyloidoses. Protein misfolding and aggregation is also increasingly recognized as the underlying cause of other health problems, including atherosclerosis and immunogenicity of biopharmaceuticals. This raises the question how nature deals with the removal of obsolete proteins in order to avoid their accumulation and disease. In recent years two proteases, tPA and factor XII, have been identified that specifically recognize aggregates of misfolded proteins. We here review these discoveries that have uncovered new roles for the fibrinolytic system and the contact activation system beyond haemostasis.


Asunto(s)
Coagulación Sanguínea , Fibrinólisis , Inflamación/metabolismo , Proteínas/metabolismo , Bradiquinina/metabolismo , Factor XII/metabolismo , Fibronectinas/metabolismo , Hemostasis , Humanos , Calicreínas/metabolismo , Cininas/metabolismo , Pliegue de Proteína , Activador de Tejido Plasminógeno/metabolismo
2.
Amyloid ; 15(3): 166-80, 2008 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-18925455

RESUMEN

The serine protease tissue-type plasminogen activator (tPA), a key enzyme in hemostasis, is activated by protein aggregates with amyloid-like properties. tPA is implicated in various pathologies, including amyloidoses. A major task is to further elucidate the mechanisms of amyloid pathology. We here show that the fibronectin type I domain of tPA mediates the interaction with amyloid protein aggregates. We found that in contrast to full-length tPA, a deletion-mutant of tPA, lacking the first three N-terminal domains (including the fibronectin type I domain), fails to activate in response to amyloid protein aggregates. Using recombinantly produced domains of tPA in direct binding assays, we subsequently mapped the amyloid-binding region to the fibronectin type I domain. This domain co-localized with congophilic plaques in brain sections from patients with Alzheimer's disease. Fibronectin type I domains from homologous proteases factor XII, hepatocyte growth factor activator and from the extracellular matrix protein fibronectin also bound to aggregated amyloidogenic peptides. Finally, we demonstrated that the isolated fibronectin type I domain inhibits amyloid-induced aggregation of blood platelets. The identification of the fibronectin type I domain as an amyloid-binding module provides new insights into the (patho-) physiological role of tPA and the homologous proteins which may offer new targets for intervention in amyloid pathology.


Asunto(s)
Péptidos beta-Amiloides/metabolismo , Amiloide/metabolismo , Factor XII/metabolismo , Fibronectinas/metabolismo , Serina Endopeptidasas/metabolismo , Activador de Tejido Plasminógeno/metabolismo , Amiloide/química , Péptidos beta-Amiloides/química , Sitios de Unión , Ensayo de Inmunoadsorción Enzimática , Factor XII/química , Fibrinolisina/metabolismo , Fibronectinas/química , Humanos , Microscopía Fluorescente , Fragmentos de Péptidos/química , Fragmentos de Péptidos/metabolismo , Agregación Plaquetaria , Unión Proteica , Estructura Terciaria de Proteína , Proteínas Recombinantes/química , Proteínas Recombinantes/metabolismo , Serina Endopeptidasas/química , Activador de Tejido Plasminógeno/química
3.
J Clin Invest ; 118(9): 3208-18, 2008 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-18725990

RESUMEN

When blood is exposed to negatively charged surface materials such as glass, an enzymatic cascade known as the contact system becomes activated. This cascade is initiated by autoactivation of Factor XII and leads to both coagulation (via Factor XI) and an inflammatory response (via the kallikrein-kinin system). However, while Factor XII is important for coagulation in vitro, it is not important for physiological hemostasis, so the physiological role of the contact system remains elusive. Using patient blood samples and isolated proteins, we identified a novel class of Factor XII activators. Factor XII was activated by misfolded protein aggregates that formed by denaturation or by surface adsorption, which specifically led to the activation of the kallikrein-kinin system without inducing coagulation. Consistent with this, we found that Factor XII, but not Factor XI, was activated and kallikrein was formed in blood from patients with systemic amyloidosis, a disease marked by the accumulation and deposition of misfolded plasma proteins. These results show that the kallikrein-kinin system can be activated by Factor XII, in a process separate from the coagulation cascade, and point to a protective role for Factor XII following activation by misfolded protein aggregates.


Asunto(s)
Factor XII/química , Calicreínas/química , Adsorción , Coagulación Sanguínea , Dicroismo Circular , Factor XI/metabolismo , Factor XII/metabolismo , Humanos , Inflamación , Caolín/química , Microscopía Electrónica de Transmisión , Modelos Biológicos , Desnaturalización Proteica , Pliegue de Proteína , Estructura Secundaria de Proteína , Factores de Tiempo
4.
Arterioscler Thromb Vasc Biol ; 27(7): 1657-65, 2007 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-17510465

RESUMEN

OBJECTIVE: Protein misfolding diseases result from the deposition of insoluble protein aggregates that often contain fibrils called amyloid. Amyloids are found in Alzheimer disease, atherosclerosis, diabetes mellitus, and systemic amyloidosis, which are diseases where platelet activation might be implicated. METHODS AND RESULTS: We induced amyloid properties in 6 unrelated proteins and found that all induced platelet aggregation in contrast to fresh controls. Amyloid-induced platelet aggregation was independent of thromboxane A2 formation and ADP secretion but enhanced by feedback stimulation through these pathways. Treatments that raised cAMP (iloprost), sequestered Ca2+ (BAPTA-AM) or prevented amyloid-platelet interaction (sRAGE, tissue-type plasminogen activator [tPA]) induced almost complete inhibition. Modulation of the function of CD36 (CD36-/- mice), p38(MAPK) (SB203580), COX-1 (indomethacin), and glycoprotein Ib alpha (Nk-protease, 6D1 antibody) induced approximately 50% inhibition. Interference with fibrinogen binding (RGDS) revealed a major contribution of alphaIIb beta3-independent aggregation (agglutination). CONCLUSIONS: Protein misfolding resulting in the appearance of amyloid induces platelet aggregation. Amyloid activates platelets through 2 pathways: one is through CD36, p38(MAPK), thromboxane A2-mediated induction of aggregation; the other is through glycoprotein Ib alpha-mediated aggregation and agglutination. The platelet stimulating properties of amyloid might explain the enhanced platelet activation observed in many diseases accompanied by the appearance of misfolded proteins with amyloid.


Asunto(s)
Amiloide/farmacología , Plaquetas/citología , Activación Plaquetaria/efectos de los fármacos , Activación Plaquetaria/fisiología , Inhibidores de Agregación Plaquetaria/farmacología , Plaquetas/metabolismo , Antígenos CD36/metabolismo , Células Cultivadas , Humanos , Agregación Plaquetaria/fisiología , Inhibidores de Agregación Plaquetaria/metabolismo , Complejo GPIb-IX de Glicoproteína Plaquetaria/metabolismo , Valores de Referencia , Sensibilidad y Especificidad , Tromboxano A2/metabolismo , Activador de Tejido Plasminógeno/metabolismo
5.
J Biol Chem ; 282(4): 2229-36, 2007 Jan 26.
Artículo en Inglés | MEDLINE | ID: mdl-17135263

RESUMEN

For largely unknown reasons, biopharmaceuticals evoke potentially harmful antibody formation. Such antibodies can inhibit drug efficacy and, when directed against endogenous proteins, cause life-threatening complications. Insight into the mechanisms by which biopharmaceuticals break tolerance and induce an immune response will contribute to finding solutions to prevent this adverse effect. Using a transgenic mouse model, we here demonstrate that protein misfolding, detected with the use of tissue-type plasminogen activator and thioflavin T, markers of amyloid-like properties, results in breaking of tolerance. In wild-type mice, misfolding enhances protein immunogenicity. Several commercially available biopharmaceutical products were found to contain misfolded proteins. In some cases, the level of misfolded protein was found to increase upon storage under conditions prescribed by the manufacturer. Our results indicate that misfolding of therapeutic proteins is an immunogenic signal and a risk factor for immunogenicity. These findings offer novel possibilities to detect immunogenic protein entities with tPA and reduce immunogenicity of biopharmaceuticals.


Asunto(s)
Formación de Anticuerpos , Pliegue de Proteína , Proteínas , Animales , Anticuerpos/inmunología , Biofarmacia , Femenino , Humanos , Inmunización , Interferón alfa-2 , Interferón-alfa/química , Interferón-alfa/inmunología , Ratones , Ratones Endogámicos BALB C , Ovalbúmina/química , Ovalbúmina/inmunología , Proteínas/química , Proteínas/inmunología , Proteínas Recombinantes/química , Proteínas Recombinantes/inmunología
6.
Nat Rev Microbiol ; 3(4): 333-41, 2005 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-15806095

RESUMEN

Amyloids are filamentous protein structures approximately 10 nm wide and 0.1-10 mum long that share a structural motif, the cross-beta structure. These fibrils are usually associated with degenerative diseases in mammals. However, recent research has shown that these proteins are also expressed on bacterial and fungal cell surfaces. Microbial amyloids are important in mediating mechanical invasion of abiotic and biotic substrates. In animal hosts, evidence indicates that these protein structures also contribute to colonization by activating host proteases that are involved in haemostasis, inflammation and remodelling of the extracellular matrix. Activation of proteases by amyloids is also implicated in modulating blood coagulation, resulting in potentially life-threatening complications.


Asunto(s)
Amiloide/fisiología , Bacterias/metabolismo , Proteínas Bacterianas/fisiología , Proteínas Fúngicas/fisiología , Hongos/metabolismo , Amiloide/química , Amiloide/genética , Animales , Bacterias/patogenicidad , Bacterias/ultraestructura , Cápsulas Bacterianas/química , Cápsulas Bacterianas/metabolismo , Infecciones Bacterianas/inmunología , Infecciones Bacterianas/microbiología , Proteínas Bacterianas/química , Proteínas Bacterianas/genética , Proteínas Fúngicas/química , Proteínas Fúngicas/genética , Hongos/patogenicidad , Hemostasis , Humanos , Hifa/química , Hifa/metabolismo , Inmunidad Innata , Micosis/inmunología , Micosis/microbiología , Proteínas/metabolismo
7.
Mol Cell Neurosci ; 28(3): 496-508, 2005 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-15737740

RESUMEN

A major component of neuritic plaques in brain tissue of Alzheimer's disease patients is the beta-amyloid peptide (Abeta). Accumulation of Abeta has been associated with increased neuronal cell death and cognitive decline. We have previously shown that amyloid peptides like Abeta bind tissue-type plasminogen activator (tPA) and stimulate plasmin production. Here we investigated how Abeta regulates plasmin formation by N1E-115 neuroblastoma cells and the effects of Abeta-mediated plasmin formation on cell attachment and cell survival. We find that Abeta induces excessive cell-associated plasmin generation that causes cell detachment. Cell detachment is inhibited by carboxypeptidase B (CPB), an enzyme that blocks plasmin formation by cleaving off C-terminal lysine residues. Plasmin and CPB control Abeta-induced cell detachment independently of direct effects on cell viability. Abeta40 as well as oligomeric and fibrillar forms of Abeta42 stimulated tPA-mediated plasminogen activation and cell detachment. Our results suggest that plasmin-mediated cell detachment could contribute to the pathological effects of Abeta in diseased brain.


Asunto(s)
Enfermedad de Alzheimer/metabolismo , Péptidos beta-Amiloides/metabolismo , Fibrinolisina/biosíntesis , Neuronas/metabolismo , Placa Amiloide/metabolismo , Plasminógeno/metabolismo , Enfermedad de Alzheimer/fisiopatología , Péptidos beta-Amiloides/farmacología , Animales , Carboxipeptidasa B/metabolismo , Carboxipeptidasa B/farmacología , Adhesión Celular/efectos de los fármacos , Adhesión Celular/fisiología , Supervivencia Celular/efectos de los fármacos , Supervivencia Celular/fisiología , Ratones , Neuroblastoma , Neuronas/efectos de los fármacos , Neuronas/patología , Fragmentos de Péptidos/metabolismo , Fragmentos de Péptidos/farmacología , Unión Proteica/fisiología , Activador de Tejido Plasminógeno/metabolismo , Células Tumorales Cultivadas
8.
J Biol Chem ; 278(43): 41810-9, 2003 Oct 24.
Artículo en Inglés | MEDLINE | ID: mdl-12909637

RESUMEN

Amyloid fibrils are components of proteinaceous plaques that are associated with conformational diseases such as Alzheimer's disease, transmissible spongiform encephalopathies, and familial amyloidosis. Amyloid polypeptides share a specific quarternary structure element known as cross-beta structure. Commonly, fibrillar aggregates are modified by advanced glycation end products (AGE). In addition, AGE formation itself induces protein aggregation. Both amyloid proteins and protein-AGE adducts bind multiligand receptors, such as receptor for AGE, CD36, and scavenger receptors A and B type I, and the serine protease tissue-type plasminogen activator (tPA). Based on these observations, we hypothesized that glycation induces refolding of globular proteins, accompanied by formation of cross-beta structure. Using transmission electron microscopy, we demonstrate here that glycated albumin condensates into fibrous or amorphous aggregates. These aggregates bind to amyloid-specific dyes Congo red and thioflavin T and to tPA. In contrast to globular albumin, glycated albumin contains amino acid residues in beta-sheet conformation, as measured with circular dichroism spectropolarimetry. Moreover, it displays cross-beta structure, as determined with x-ray fiber diffraction. We conclude that glycation induces refolding of initially globular albumin into amyloid fibrils comprising cross-beta structure. This would explain how glycated ligands and amyloid ligands can bind to the same multiligand "cross-beta structure" receptors and to tPA.


Asunto(s)
Amiloide/química , Albúmina Sérica/química , Albúmina Sérica/metabolismo , Animales , Benzotiazoles , Muerte Celular/efectos de los fármacos , Línea Celular , Rojo Congo , Dimerización , Productos Finales de Glicación Avanzada/química , Productos Finales de Glicación Avanzada/farmacología , Glicosilación , Ratones , Microscopía Electrónica , Desnaturalización Proteica , Pliegue de Proteína , Estructura Cuaternaria de Proteína , Estructura Secundaria de Proteína , Tiazoles , Activador de Tejido Plasminógeno/metabolismo
9.
J Biol Chem ; 278(17): 15035-9, 2003 Apr 25.
Artículo en Inglés | MEDLINE | ID: mdl-12582178

RESUMEN

The multimeric glycoprotein von Willebrand factor (VWF) mediates platelet adhesion to collagen at sites of vascular damage. The binding site for collagen types I and III is located in the VWF-A3 domain. Recently, we showed that His(1023), located near the edge between the "front" and "bottom" faces of A3, is critical for collagen binding (Romijn, R. A., Bouma, B., Wuyster, W., Gros, P., Kroon, J., Sixma, J. J., and Huizinga, E. G. (2001) J. Biol. Chem. 276, 9985-9991). To map the binding site in detail, we introduced 22 point mutations in the front and bottom faces of A3. The mutants were expressed as multimeric VWF, and binding to collagen type III was evaluated in a solid-state binding assay and by surface plasmon resonance. Mutation of residues Asp(979), Ser(1020), and His(1023) nearly abolished collagen binding, whereas mutation of residues Ile(975), Thr(977), Val(997), and Glu(1001) reduced binding affinity about 10-fold. Together, these residues define a flat and rather hydrophobic collagen-binding site located at the front face of the A3 domain. The collagen-binding site of VWF-A3 is distinctly different from that of the homologous integrin alpha(2) I domain, which has a hydrophilic binding site located at the top face of the domain. Based on the surface characteristics of the collagen-binding site of A3, we propose that it interacts with collagen sequences containing positively charged and hydrophobic residues. Docking of a collagen triple helix on the binding site suggests a range of possible engagements and predicts that at most eight consecutive residues in a collagen triple helix interact with A3.


Asunto(s)
Colágeno Tipo III/metabolismo , Factor de von Willebrand/química , Factor de von Willebrand/metabolismo , Sustitución de Aminoácidos , Sitios de Unión/genética , Dimerización , Humanos , Modelos Moleculares , Mutagénesis Sitio-Dirigida , Mapeo Peptídico , Mutación Puntual , Unión Proteica/genética , Estructura Terciaria de Proteína , Transfección , Factor de von Willebrand/genética
10.
Curr Biol ; 12(21): 1833-9, 2002 Oct 29.
Artículo en Inglés | MEDLINE | ID: mdl-12419183

RESUMEN

Tissue-type plasminogen activator (tPA) regulates fibrin clot lysis by stimulating the conversion of plasminogen into the active protease plasmin. Fibrin is required for efficient tPA-mediated plasmin generation and thereby stimulates its own proteolysis. Several fibrin regions can bind to tPA, but the structural basis for this interaction is unknown. Amyloid beta (Abeta) is a peptide aggregate that is associated with neurotoxicity in brains afflicted with Alzheimer's disease. Like fibrin, it stimulates tPA-mediated plasmin formation. Intermolecular stacking of peptide backbones in beta sheet conformation underlies cross-beta structure in amyloid peptides. We show here that fibrin-derived peptides adopt cross-beta structure and form amyloid fibers. This correlates with tPA binding and stimulation of tPA-mediated plasminogen activation. Prototype amyloid peptides, including Abeta and islet amyloid polypeptide (IAPP) (associated with pancreatic beta cell toxicity in type II diabetes), have no sequence similarity to the fibrin peptides but also bind to tPA and can substitute for fibrin in plasminogen activation by tPA. Moreover, the induction of cross-beta structure in an otherwise globular protein (endostatin) endows it with tPA-activating potential. Our results classify tPA as a multiligand receptor and show that cross-beta structure is the common denominator in tPA binding ligands.


Asunto(s)
Activador de Tejido Plasminógeno/metabolismo , Conformación Proteica , Activador de Tejido Plasminógeno/química
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA